Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sina Fellermeier-Kopf
Observed name:
S. Fellermeier-Kopf
Institution:
BioNTech (Germany)
Observed institutions:
University of Stuttgart,
BioNTech (Germany)
ORCID:
0009-0006-0402-751X
Observed ORCID:
0009-0006-0402-751X
OpenAlex ID:
A5076096680
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
2025
·
Michela Capello
, Angelica Sette
, et al.
·
Journal for ImmunoTherapy of Cancer
·
19
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
2018
·
Meike Hutt
, Sina Fellermeier-Kopf
, et al.
·
Oncotarget
·
18
PDF
Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans
2018
·
Sina Fellermeier-Kopf
, Friederike Gieseke
, et al.
·
OncoImmunology
·
11
PDF
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade
2025
·
Işıl Altıntaş
, Kristina B. Nürmberger
, et al.
·
Scientific Reports
·
2
PDF
148P HexaBody-OX40: A novel Fcγ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
2023
·
K. Kemper
, M. Köhne
, et al.
·
Immuno-Oncology Technology
·
2
PDF
739 The combination of HexaBody®-OX40 with PD-(L)1 blockade potentiates agonistic activity in vitro and antitumor activity in vivo
2024
·
Kristel Kemper
, Maarten Van der Kroef
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
731 The combination of an EpCAMx4–1BB bispecific antibody with PD-1 blockade potentiates single-agent effects on T-cell functions and enhances antitumor activity in preclinical studies
2024
·
Sina Fellermeier-Kopf
, Andrea Imle
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro
2023
·
Andrea Imle
, Isil Altintas
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
2023
·
S. Fellermeier-Kopf
, A. Ioan-Facsinay
, et al.
·
Annals of Oncology
·
1
PDF
1070 HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking
2022
·
Kristina Nürmberger
, Andrea Imle
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
An Fc-inert mouse-human chimeric variant of DuoBody®-CD40x4-1BB exhibits in vivo antitumor activity and peripheral immune modulation
2026
·
Karsten Pilones
, Angelica Sette
, et al.
·
OncoImmunology
PDF
HexaBody-OX40 Promotes Antitumor Immunity through FcγR Cross-linking–Independent OX40 Agonist Activity and Enhances Effects of PD-1 Blocking Antibodies
2026
·
Kristel Kemper
, Maren Köhne
, et al.
·
Clinical Cancer Research
Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
2026
·
Mathias Vormehr
, Lena M. Kranz
, et al.
·
Science Advances
PDF
Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response
2026
·
Ayline Kübler
, Sophie-Christin Linkenbach
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Abstract 6075: The combination of an EpCAMx4-1BB bispecific antibody with PD-1 blockade exhibits antitumor activity in a murine tumor model unresponsive to each individual antibody
2025
·
Andrea Imle
, Sina Fellermeier-Kopf
, et al.
·
Cancer Research
719 Acasunlimab combined with PD-1 blockade elicits complementary immune-modulatory effects and enhances anti-tumor activity in preclinical models
2024
·
Michela Capello
, Angelica Sette
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation
2023
·
Karsten Pilones
, Angelica Sette
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
2023
·
Michela Capello
, Angelica Sette
, et al.
·
Cancer Research
Show more works
View as search
Works count:
18
Citation count:
57
H-index:
3
I10-index:
3
Year
Topic
Type